CVS Health's strong Q2 earnings and raised 2025 profit outlook drive stock surge, reflecting investor confidence in the company's growth potential.
China's manufacturing and services sectors show further weakness, raising concerns about industrial deflation and the need for stronger policy measures to stabilize growth.
Bristol Myers Squibb exceeds Q2 revenue forecasts on strong sales of key brands like Eliquis and Opdivo.
CVS Health's strong Q2 earnings and raised 2025 profit outlook drive stock surge, reflecting investor confidence in the company's growth potential.
China's manufacturing and services sectors show further weakness, raising concerns about industrial deflation and the need for stronger policy measures to stabilize growth.
Bristol Myers Squibb exceeds Q2 revenue forecasts on strong sales of key brands like Eliquis and Opdivo.